Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/india-launches-vaccine-to-prevent-japanese-encephalitis-aarti-dhar-22908/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/india-launches-vaccine-to-prevent-japanese-encephalitis-aarti-dhar-22908/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/india-launches-vaccine-to-prevent-japanese-encephalitis-aarti-dhar-22908/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/india-launches-vaccine-to-prevent-japanese-encephalitis-aarti-dhar-22908/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6801e39740b9b-trace').style.display = (document.getElementById('cakeErr6801e39740b9b-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr6801e39740b9b-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6801e39740b9b-code').style.display = (document.getElementById('cakeErr6801e39740b9b-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr6801e39740b9b-context').style.display = (document.getElementById('cakeErr6801e39740b9b-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr6801e39740b9b-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr6801e39740b9b-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 22754,
		&#039;title&#039; =&gt; &#039;India launches vaccine to prevent Japanese encephalitis-Aarti Dhar&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;JENVAC is the first vaccine to be manufactured in the public-private partnership mode&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
India on Friday launched its first indigenous vaccine to protect children from Japanese encephalitis. Until now, the country has been importing the vaccine from China.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Vero cell-derived purified inactivated JE vaccine-JENVAC, which received manufacturing and marketing approvals from the Drug Controller General of India, is the first vaccine to be manufactured in the public-private partnership mode between the Indian Council of Medical Research and Bharat Biotech.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The vaccine will provide increased immunogenicity and long-term protection as a result of unique manufacturing technologies.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Japanese encephalitis, a mosquito-borne viral infection, is the most common cause of viral encephalitis in eastern Uttar Pradesh (U.P.), affecting 171 districts and claiming hundreds of lives every year. Mortality is higher among children and thousands of them in this area have been rendered disabled by it.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The virus strain for this vaccine was isolated in Kolar, Karnataka, during the early 1980s and characterised by the National Institute of Virology at Pune. The strains were transferred to Bharat Biotech for further vaccine development.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The most significant benefit JENVAC brings over live attenuated vaccines (those that reduce the harmful effects of pathogens but keep them viable) is that it can be administered during an epidemic as it is a highly purified and inactivated vaccine.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In the clinical trials, JENVAC showed superior safety and immunogenicity, in comparison to live vaccine. It met all its primary and secondary endpoints in the age group of 1-50 years, after 1 or 2 doses in vaccination. Phase III trials showed 98.7 per cent sero-protection 28 days after the first dose, and 99.8 per cent sero-protection 28 days after the second dose.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The results proved that JENVAC can be administered as a single dose during epidemics for mass vaccination campaigns and also as a two-dose schedule during routine immunisation as part of the National immunisation programme in endemic regions.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Bharat Biotech will pursue a dual pricing strategy for JENVAC to cater to the needs of government and private agencies. While the price is expected to be around Rs 160 per dose in the open market, the price for government agencies is still being negotiated.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Describing the vaccine as an &amp;quot;Indian solution for an Indian problem&amp;quot;, Union Health and Family Welfare Minister Ghulam Nabi Azad said this completely indigenous vaccine was an outstanding example of public-private partnership and a remarkable milestone in the emergence of India as an innovative and self-sufficient technology hub.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Since we were using a vaccine imported from China, availability was certainly an issue for comprehensive and quick augmentation of the national programme,&amp;quot; he said, adding that the need for this vaccine was immense since the birth cohort in the affected 171 districts was about 40 lakh annually, requiring about 1 crore doses for a comprehensive coverage.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The current manufacturing capacity of JENVAC is 20 million doses, expandable to 60 million doses based on market requirements. The vaccine is available in both single dose and 5 dose presentations, Krishna M. Ella, Chairman and Managing Director of Bharat Biotech said. &amp;quot;It is yet another milestone for Bharat Biotech.&amp;quot; 
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu, 4 October, 2013, http://www.thehindu.com/news/national/india-launches-vaccine-to-prevent-japanese-encephalitis/article5201813.ece?homepage=true&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;india-launches-vaccine-to-prevent-japanese-encephalitis-aarti-dhar-22908&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 22908,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 22754,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | India launches vaccine to prevent Japanese encephalitis-Aarti Dhar&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Vaccination,Encephalitis,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Hindu



JENVAC is the first vaccine to be manufactured in the public-private partnership mode


India on Friday launched its first indigenous vaccine to protect children from Japanese encephalitis. Until now, the country has been importing the vaccine from China.


The Vero cell-derived...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;JENVAC is the first vaccine to be manufactured in the public-private partnership mode&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;India on Friday launched its first indigenous vaccine to protect children from Japanese encephalitis. Until now, the country has been importing the vaccine from China.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Vero cell-derived purified inactivated JE vaccine-JENVAC, which received manufacturing and marketing approvals from the Drug Controller General of India, is the first vaccine to be manufactured in the public-private partnership mode between the Indian Council of Medical Research and Bharat Biotech.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The vaccine will provide increased immunogenicity and long-term protection as a result of unique manufacturing technologies.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Japanese encephalitis, a mosquito-borne viral infection, is the most common cause of viral encephalitis in eastern Uttar Pradesh (U.P.), affecting 171 districts and claiming hundreds of lives every year. Mortality is higher among children and thousands of them in this area have been rendered disabled by it.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The virus strain for this vaccine was isolated in Kolar, Karnataka, during the early 1980s and characterised by the National Institute of Virology at Pune. The strains were transferred to Bharat Biotech for further vaccine development.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The most significant benefit JENVAC brings over live attenuated vaccines (those that reduce the harmful effects of pathogens but keep them viable) is that it can be administered during an epidemic as it is a highly purified and inactivated vaccine.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In the clinical trials, JENVAC showed superior safety and immunogenicity, in comparison to live vaccine. It met all its primary and secondary endpoints in the age group of 1-50 years, after 1 or 2 doses in vaccination. Phase III trials showed 98.7 per cent sero-protection 28 days after the first dose, and 99.8 per cent sero-protection 28 days after the second dose.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The results proved that JENVAC can be administered as a single dose during epidemics for mass vaccination campaigns and also as a two-dose schedule during routine immunisation as part of the National immunisation programme in endemic regions.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Bharat Biotech will pursue a dual pricing strategy for JENVAC to cater to the needs of government and private agencies. While the price is expected to be around Rs 160 per dose in the open market, the price for government agencies is still being negotiated.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Describing the vaccine as an &amp;quot;Indian solution for an Indian problem&amp;quot;, Union Health and Family Welfare Minister Ghulam Nabi Azad said this completely indigenous vaccine was an outstanding example of public-private partnership and a remarkable milestone in the emergence of India as an innovative and self-sufficient technology hub.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Since we were using a vaccine imported from China, availability was certainly an issue for comprehensive and quick augmentation of the national programme,&amp;quot; he said, adding that the need for this vaccine was immense since the birth cohort in the affected 171 districts was about 40 lakh annually, requiring about 1 crore doses for a comprehensive coverage.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The current manufacturing capacity of JENVAC is 20 million doses, expandable to 60 million doses based on market requirements. The vaccine is available in both single dose and 5 dose presentations, Krishna M. Ella, Chairman and Managing Director of Bharat Biotech said. &amp;quot;It is yet another milestone for Bharat Biotech.&amp;quot; &lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 22754,
	&#039;title&#039; =&gt; &#039;India launches vaccine to prevent Japanese encephalitis-Aarti Dhar&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;JENVAC is the first vaccine to be manufactured in the public-private partnership mode&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
India on Friday launched its first indigenous vaccine to protect children from Japanese encephalitis. Until now, the country has been importing the vaccine from China.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Vero cell-derived purified inactivated JE vaccine-JENVAC, which received manufacturing and marketing approvals from the Drug Controller General of India, is the first vaccine to be manufactured in the public-private partnership mode between the Indian Council of Medical Research and Bharat Biotech.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The vaccine will provide increased immunogenicity and long-term protection as a result of unique manufacturing technologies.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Japanese encephalitis, a mosquito-borne viral infection, is the most common cause of viral encephalitis in eastern Uttar Pradesh (U.P.), affecting 171 districts and claiming hundreds of lives every year. Mortality is higher among children and thousands of them in this area have been rendered disabled by it.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The virus strain for this vaccine was isolated in Kolar, Karnataka, during the early 1980s and characterised by the National Institute of Virology at Pune. The strains were transferred to Bharat Biotech for further vaccine development.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The most significant benefit JENVAC brings over live attenuated vaccines (those that reduce the harmful effects of pathogens but keep them viable) is that it can be administered during an epidemic as it is a highly purified and inactivated vaccine.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In the clinical trials, JENVAC showed superior safety and immunogenicity, in comparison to live vaccine. It met all its primary and secondary endpoints in the age group of 1-50 years, after 1 or 2 doses in vaccination. Phase III trials showed 98.7 per cent sero-protection 28 days after the first dose, and 99.8 per cent sero-protection 28 days after the second dose.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The results proved that JENVAC can be administered as a single dose during epidemics for mass vaccination campaigns and also as a two-dose schedule during routine immunisation as part of the National immunisation programme in endemic regions.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Bharat Biotech will pursue a dual pricing strategy for JENVAC to cater to the needs of government and private agencies. While the price is expected to be around Rs 160 per dose in the open market, the price for government agencies is still being negotiated.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Describing the vaccine as an &amp;quot;Indian solution for an Indian problem&amp;quot;, Union Health and Family Welfare Minister Ghulam Nabi Azad said this completely indigenous vaccine was an outstanding example of public-private partnership and a remarkable milestone in the emergence of India as an innovative and self-sufficient technology hub.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Since we were using a vaccine imported from China, availability was certainly an issue for comprehensive and quick augmentation of the national programme,&amp;quot; he said, adding that the need for this vaccine was immense since the birth cohort in the affected 171 districts was about 40 lakh annually, requiring about 1 crore doses for a comprehensive coverage.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The current manufacturing capacity of JENVAC is 20 million doses, expandable to 60 million doses based on market requirements. The vaccine is available in both single dose and 5 dose presentations, Krishna M. Ella, Chairman and Managing Director of Bharat Biotech said. &amp;quot;It is yet another milestone for Bharat Biotech.&amp;quot; 
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu, 4 October, 2013, http://www.thehindu.com/news/national/india-launches-vaccine-to-prevent-japanese-encephalitis/article5201813.ece?homepage=true&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;india-launches-vaccine-to-prevent-japanese-encephalitis-aarti-dhar-22908&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 22908,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 22754
$metaTitle = &#039;LATEST NEWS UPDATES | India launches vaccine to prevent Japanese encephalitis-Aarti Dhar&#039;
$metaKeywords = &#039;Vaccination,Encephalitis,Health&#039;
$metaDesc = &#039;
-The Hindu



JENVAC is the first vaccine to be manufactured in the public-private partnership mode


India on Friday launched its first indigenous vaccine to protect children from Japanese encephalitis. Until now, the country has been importing the vaccine from China.


The Vero cell-derived...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;JENVAC is the first vaccine to be manufactured in the public-private partnership mode&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;India on Friday launched its first indigenous vaccine to protect children from Japanese encephalitis. Until now, the country has been importing the vaccine from China.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Vero cell-derived purified inactivated JE vaccine-JENVAC, which received manufacturing and marketing approvals from the Drug Controller General of India, is the first vaccine to be manufactured in the public-private partnership mode between the Indian Council of Medical Research and Bharat Biotech.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The vaccine will provide increased immunogenicity and long-term protection as a result of unique manufacturing technologies.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Japanese encephalitis, a mosquito-borne viral infection, is the most common cause of viral encephalitis in eastern Uttar Pradesh (U.P.), affecting 171 districts and claiming hundreds of lives every year. Mortality is higher among children and thousands of them in this area have been rendered disabled by it.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The virus strain for this vaccine was isolated in Kolar, Karnataka, during the early 1980s and characterised by the National Institute of Virology at Pune. The strains were transferred to Bharat Biotech for further vaccine development.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The most significant benefit JENVAC brings over live attenuated vaccines (those that reduce the harmful effects of pathogens but keep them viable) is that it can be administered during an epidemic as it is a highly purified and inactivated vaccine.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In the clinical trials, JENVAC showed superior safety and immunogenicity, in comparison to live vaccine. It met all its primary and secondary endpoints in the age group of 1-50 years, after 1 or 2 doses in vaccination. Phase III trials showed 98.7 per cent sero-protection 28 days after the first dose, and 99.8 per cent sero-protection 28 days after the second dose.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The results proved that JENVAC can be administered as a single dose during epidemics for mass vaccination campaigns and also as a two-dose schedule during routine immunisation as part of the National immunisation programme in endemic regions.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Bharat Biotech will pursue a dual pricing strategy for JENVAC to cater to the needs of government and private agencies. While the price is expected to be around Rs 160 per dose in the open market, the price for government agencies is still being negotiated.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Describing the vaccine as an &amp;quot;Indian solution for an Indian problem&amp;quot;, Union Health and Family Welfare Minister Ghulam Nabi Azad said this completely indigenous vaccine was an outstanding example of public-private partnership and a remarkable milestone in the emergence of India as an innovative and self-sufficient technology hub.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Since we were using a vaccine imported from China, availability was certainly an issue for comprehensive and quick augmentation of the national programme,&amp;quot; he said, adding that the need for this vaccine was immense since the birth cohort in the affected 171 districts was about 40 lakh annually, requiring about 1 crore doses for a comprehensive coverage.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The current manufacturing capacity of JENVAC is 20 million doses, expandable to 60 million doses based on market requirements. The vaccine is available in both single dose and 5 dose presentations, Krishna M. Ella, Chairman and Managing Director of Bharat Biotech said. &amp;quot;It is yet another milestone for Bharat Biotech.&amp;quot; &lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/india-launches-vaccine-to-prevent-japanese-encephalitis-aarti-dhar-22908.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | India launches vaccine to prevent Japanese encephalitis-Aarti Dhar | Im4change.org</title>
    <meta name="description" content="
-The Hindu



JENVAC is the first vaccine to be manufactured in the public-private partnership mode


India on Friday launched its first indigenous vaccine to protect children from Japanese encephalitis. Until now, the country has been importing the vaccine from China.


The Vero cell-derived..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>India launches vaccine to prevent Japanese encephalitis-Aarti Dhar</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Hindu</div><p align="justify"><br /><em>JENVAC is the first vaccine to be manufactured in the public-private partnership mode</em></p><p align="justify">India on Friday launched its first indigenous vaccine to protect children from Japanese encephalitis. Until now, the country has been importing the vaccine from China.</p><p align="justify">The Vero cell-derived purified inactivated JE vaccine-JENVAC, which received manufacturing and marketing approvals from the Drug Controller General of India, is the first vaccine to be manufactured in the public-private partnership mode between the Indian Council of Medical Research and Bharat Biotech.</p><p align="justify">The vaccine will provide increased immunogenicity and long-term protection as a result of unique manufacturing technologies.</p><p align="justify">Japanese encephalitis, a mosquito-borne viral infection, is the most common cause of viral encephalitis in eastern Uttar Pradesh (U.P.), affecting 171 districts and claiming hundreds of lives every year. Mortality is higher among children and thousands of them in this area have been rendered disabled by it.</p><p align="justify">The virus strain for this vaccine was isolated in Kolar, Karnataka, during the early 1980s and characterised by the National Institute of Virology at Pune. The strains were transferred to Bharat Biotech for further vaccine development.</p><p align="justify">The most significant benefit JENVAC brings over live attenuated vaccines (those that reduce the harmful effects of pathogens but keep them viable) is that it can be administered during an epidemic as it is a highly purified and inactivated vaccine.</p><p align="justify">In the clinical trials, JENVAC showed superior safety and immunogenicity, in comparison to live vaccine. It met all its primary and secondary endpoints in the age group of 1-50 years, after 1 or 2 doses in vaccination. Phase III trials showed 98.7 per cent sero-protection 28 days after the first dose, and 99.8 per cent sero-protection 28 days after the second dose.</p><p align="justify">The results proved that JENVAC can be administered as a single dose during epidemics for mass vaccination campaigns and also as a two-dose schedule during routine immunisation as part of the National immunisation programme in endemic regions.</p><p align="justify">Bharat Biotech will pursue a dual pricing strategy for JENVAC to cater to the needs of government and private agencies. While the price is expected to be around Rs 160 per dose in the open market, the price for government agencies is still being negotiated.</p><p align="justify">Describing the vaccine as an &quot;Indian solution for an Indian problem&quot;, Union Health and Family Welfare Minister Ghulam Nabi Azad said this completely indigenous vaccine was an outstanding example of public-private partnership and a remarkable milestone in the emergence of India as an innovative and self-sufficient technology hub.</p><p align="justify">&quot;Since we were using a vaccine imported from China, availability was certainly an issue for comprehensive and quick augmentation of the national programme,&quot; he said, adding that the need for this vaccine was immense since the birth cohort in the affected 171 districts was about 40 lakh annually, requiring about 1 crore doses for a comprehensive coverage.</p><p align="justify">The current manufacturing capacity of JENVAC is 20 million doses, expandable to 60 million doses based on market requirements. The vaccine is available in both single dose and 5 dose presentations, Krishna M. Ella, Chairman and Managing Director of Bharat Biotech said. &quot;It is yet another milestone for Bharat Biotech.&quot; </p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6801e39740b9b-trace').style.display = (document.getElementById('cakeErr6801e39740b9b-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr6801e39740b9b-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6801e39740b9b-code').style.display = (document.getElementById('cakeErr6801e39740b9b-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr6801e39740b9b-context').style.display = (document.getElementById('cakeErr6801e39740b9b-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr6801e39740b9b-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr6801e39740b9b-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 22754,
		&#039;title&#039; =&gt; &#039;India launches vaccine to prevent Japanese encephalitis-Aarti Dhar&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;JENVAC is the first vaccine to be manufactured in the public-private partnership mode&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
India on Friday launched its first indigenous vaccine to protect children from Japanese encephalitis. Until now, the country has been importing the vaccine from China.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Vero cell-derived purified inactivated JE vaccine-JENVAC, which received manufacturing and marketing approvals from the Drug Controller General of India, is the first vaccine to be manufactured in the public-private partnership mode between the Indian Council of Medical Research and Bharat Biotech.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The vaccine will provide increased immunogenicity and long-term protection as a result of unique manufacturing technologies.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Japanese encephalitis, a mosquito-borne viral infection, is the most common cause of viral encephalitis in eastern Uttar Pradesh (U.P.), affecting 171 districts and claiming hundreds of lives every year. Mortality is higher among children and thousands of them in this area have been rendered disabled by it.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The virus strain for this vaccine was isolated in Kolar, Karnataka, during the early 1980s and characterised by the National Institute of Virology at Pune. The strains were transferred to Bharat Biotech for further vaccine development.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The most significant benefit JENVAC brings over live attenuated vaccines (those that reduce the harmful effects of pathogens but keep them viable) is that it can be administered during an epidemic as it is a highly purified and inactivated vaccine.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In the clinical trials, JENVAC showed superior safety and immunogenicity, in comparison to live vaccine. It met all its primary and secondary endpoints in the age group of 1-50 years, after 1 or 2 doses in vaccination. Phase III trials showed 98.7 per cent sero-protection 28 days after the first dose, and 99.8 per cent sero-protection 28 days after the second dose.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The results proved that JENVAC can be administered as a single dose during epidemics for mass vaccination campaigns and also as a two-dose schedule during routine immunisation as part of the National immunisation programme in endemic regions.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Bharat Biotech will pursue a dual pricing strategy for JENVAC to cater to the needs of government and private agencies. While the price is expected to be around Rs 160 per dose in the open market, the price for government agencies is still being negotiated.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Describing the vaccine as an &amp;quot;Indian solution for an Indian problem&amp;quot;, Union Health and Family Welfare Minister Ghulam Nabi Azad said this completely indigenous vaccine was an outstanding example of public-private partnership and a remarkable milestone in the emergence of India as an innovative and self-sufficient technology hub.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Since we were using a vaccine imported from China, availability was certainly an issue for comprehensive and quick augmentation of the national programme,&amp;quot; he said, adding that the need for this vaccine was immense since the birth cohort in the affected 171 districts was about 40 lakh annually, requiring about 1 crore doses for a comprehensive coverage.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The current manufacturing capacity of JENVAC is 20 million doses, expandable to 60 million doses based on market requirements. The vaccine is available in both single dose and 5 dose presentations, Krishna M. Ella, Chairman and Managing Director of Bharat Biotech said. &amp;quot;It is yet another milestone for Bharat Biotech.&amp;quot; 
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu, 4 October, 2013, http://www.thehindu.com/news/national/india-launches-vaccine-to-prevent-japanese-encephalitis/article5201813.ece?homepage=true&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;india-launches-vaccine-to-prevent-japanese-encephalitis-aarti-dhar-22908&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 22908,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 22754,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | India launches vaccine to prevent Japanese encephalitis-Aarti Dhar&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Vaccination,Encephalitis,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Hindu



JENVAC is the first vaccine to be manufactured in the public-private partnership mode


India on Friday launched its first indigenous vaccine to protect children from Japanese encephalitis. Until now, the country has been importing the vaccine from China.


The Vero cell-derived...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;JENVAC is the first vaccine to be manufactured in the public-private partnership mode&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;India on Friday launched its first indigenous vaccine to protect children from Japanese encephalitis. Until now, the country has been importing the vaccine from China.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Vero cell-derived purified inactivated JE vaccine-JENVAC, which received manufacturing and marketing approvals from the Drug Controller General of India, is the first vaccine to be manufactured in the public-private partnership mode between the Indian Council of Medical Research and Bharat Biotech.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The vaccine will provide increased immunogenicity and long-term protection as a result of unique manufacturing technologies.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Japanese encephalitis, a mosquito-borne viral infection, is the most common cause of viral encephalitis in eastern Uttar Pradesh (U.P.), affecting 171 districts and claiming hundreds of lives every year. Mortality is higher among children and thousands of them in this area have been rendered disabled by it.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The virus strain for this vaccine was isolated in Kolar, Karnataka, during the early 1980s and characterised by the National Institute of Virology at Pune. The strains were transferred to Bharat Biotech for further vaccine development.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The most significant benefit JENVAC brings over live attenuated vaccines (those that reduce the harmful effects of pathogens but keep them viable) is that it can be administered during an epidemic as it is a highly purified and inactivated vaccine.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In the clinical trials, JENVAC showed superior safety and immunogenicity, in comparison to live vaccine. It met all its primary and secondary endpoints in the age group of 1-50 years, after 1 or 2 doses in vaccination. Phase III trials showed 98.7 per cent sero-protection 28 days after the first dose, and 99.8 per cent sero-protection 28 days after the second dose.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The results proved that JENVAC can be administered as a single dose during epidemics for mass vaccination campaigns and also as a two-dose schedule during routine immunisation as part of the National immunisation programme in endemic regions.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Bharat Biotech will pursue a dual pricing strategy for JENVAC to cater to the needs of government and private agencies. While the price is expected to be around Rs 160 per dose in the open market, the price for government agencies is still being negotiated.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Describing the vaccine as an &amp;quot;Indian solution for an Indian problem&amp;quot;, Union Health and Family Welfare Minister Ghulam Nabi Azad said this completely indigenous vaccine was an outstanding example of public-private partnership and a remarkable milestone in the emergence of India as an innovative and self-sufficient technology hub.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Since we were using a vaccine imported from China, availability was certainly an issue for comprehensive and quick augmentation of the national programme,&amp;quot; he said, adding that the need for this vaccine was immense since the birth cohort in the affected 171 districts was about 40 lakh annually, requiring about 1 crore doses for a comprehensive coverage.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The current manufacturing capacity of JENVAC is 20 million doses, expandable to 60 million doses based on market requirements. The vaccine is available in both single dose and 5 dose presentations, Krishna M. Ella, Chairman and Managing Director of Bharat Biotech said. &amp;quot;It is yet another milestone for Bharat Biotech.&amp;quot; &lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 22754,
	&#039;title&#039; =&gt; &#039;India launches vaccine to prevent Japanese encephalitis-Aarti Dhar&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;JENVAC is the first vaccine to be manufactured in the public-private partnership mode&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
India on Friday launched its first indigenous vaccine to protect children from Japanese encephalitis. Until now, the country has been importing the vaccine from China.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Vero cell-derived purified inactivated JE vaccine-JENVAC, which received manufacturing and marketing approvals from the Drug Controller General of India, is the first vaccine to be manufactured in the public-private partnership mode between the Indian Council of Medical Research and Bharat Biotech.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The vaccine will provide increased immunogenicity and long-term protection as a result of unique manufacturing technologies.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Japanese encephalitis, a mosquito-borne viral infection, is the most common cause of viral encephalitis in eastern Uttar Pradesh (U.P.), affecting 171 districts and claiming hundreds of lives every year. Mortality is higher among children and thousands of them in this area have been rendered disabled by it.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The virus strain for this vaccine was isolated in Kolar, Karnataka, during the early 1980s and characterised by the National Institute of Virology at Pune. The strains were transferred to Bharat Biotech for further vaccine development.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The most significant benefit JENVAC brings over live attenuated vaccines (those that reduce the harmful effects of pathogens but keep them viable) is that it can be administered during an epidemic as it is a highly purified and inactivated vaccine.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In the clinical trials, JENVAC showed superior safety and immunogenicity, in comparison to live vaccine. It met all its primary and secondary endpoints in the age group of 1-50 years, after 1 or 2 doses in vaccination. Phase III trials showed 98.7 per cent sero-protection 28 days after the first dose, and 99.8 per cent sero-protection 28 days after the second dose.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The results proved that JENVAC can be administered as a single dose during epidemics for mass vaccination campaigns and also as a two-dose schedule during routine immunisation as part of the National immunisation programme in endemic regions.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Bharat Biotech will pursue a dual pricing strategy for JENVAC to cater to the needs of government and private agencies. While the price is expected to be around Rs 160 per dose in the open market, the price for government agencies is still being negotiated.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Describing the vaccine as an &amp;quot;Indian solution for an Indian problem&amp;quot;, Union Health and Family Welfare Minister Ghulam Nabi Azad said this completely indigenous vaccine was an outstanding example of public-private partnership and a remarkable milestone in the emergence of India as an innovative and self-sufficient technology hub.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Since we were using a vaccine imported from China, availability was certainly an issue for comprehensive and quick augmentation of the national programme,&amp;quot; he said, adding that the need for this vaccine was immense since the birth cohort in the affected 171 districts was about 40 lakh annually, requiring about 1 crore doses for a comprehensive coverage.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The current manufacturing capacity of JENVAC is 20 million doses, expandable to 60 million doses based on market requirements. The vaccine is available in both single dose and 5 dose presentations, Krishna M. Ella, Chairman and Managing Director of Bharat Biotech said. &amp;quot;It is yet another milestone for Bharat Biotech.&amp;quot; 
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu, 4 October, 2013, http://www.thehindu.com/news/national/india-launches-vaccine-to-prevent-japanese-encephalitis/article5201813.ece?homepage=true&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;india-launches-vaccine-to-prevent-japanese-encephalitis-aarti-dhar-22908&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 22908,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 22754
$metaTitle = &#039;LATEST NEWS UPDATES | India launches vaccine to prevent Japanese encephalitis-Aarti Dhar&#039;
$metaKeywords = &#039;Vaccination,Encephalitis,Health&#039;
$metaDesc = &#039;
-The Hindu



JENVAC is the first vaccine to be manufactured in the public-private partnership mode


India on Friday launched its first indigenous vaccine to protect children from Japanese encephalitis. Until now, the country has been importing the vaccine from China.


The Vero cell-derived...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;JENVAC is the first vaccine to be manufactured in the public-private partnership mode&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;India on Friday launched its first indigenous vaccine to protect children from Japanese encephalitis. Until now, the country has been importing the vaccine from China.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Vero cell-derived purified inactivated JE vaccine-JENVAC, which received manufacturing and marketing approvals from the Drug Controller General of India, is the first vaccine to be manufactured in the public-private partnership mode between the Indian Council of Medical Research and Bharat Biotech.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The vaccine will provide increased immunogenicity and long-term protection as a result of unique manufacturing technologies.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Japanese encephalitis, a mosquito-borne viral infection, is the most common cause of viral encephalitis in eastern Uttar Pradesh (U.P.), affecting 171 districts and claiming hundreds of lives every year. Mortality is higher among children and thousands of them in this area have been rendered disabled by it.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The virus strain for this vaccine was isolated in Kolar, Karnataka, during the early 1980s and characterised by the National Institute of Virology at Pune. The strains were transferred to Bharat Biotech for further vaccine development.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The most significant benefit JENVAC brings over live attenuated vaccines (those that reduce the harmful effects of pathogens but keep them viable) is that it can be administered during an epidemic as it is a highly purified and inactivated vaccine.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In the clinical trials, JENVAC showed superior safety and immunogenicity, in comparison to live vaccine. It met all its primary and secondary endpoints in the age group of 1-50 years, after 1 or 2 doses in vaccination. Phase III trials showed 98.7 per cent sero-protection 28 days after the first dose, and 99.8 per cent sero-protection 28 days after the second dose.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The results proved that JENVAC can be administered as a single dose during epidemics for mass vaccination campaigns and also as a two-dose schedule during routine immunisation as part of the National immunisation programme in endemic regions.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Bharat Biotech will pursue a dual pricing strategy for JENVAC to cater to the needs of government and private agencies. While the price is expected to be around Rs 160 per dose in the open market, the price for government agencies is still being negotiated.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Describing the vaccine as an &amp;quot;Indian solution for an Indian problem&amp;quot;, Union Health and Family Welfare Minister Ghulam Nabi Azad said this completely indigenous vaccine was an outstanding example of public-private partnership and a remarkable milestone in the emergence of India as an innovative and self-sufficient technology hub.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Since we were using a vaccine imported from China, availability was certainly an issue for comprehensive and quick augmentation of the national programme,&amp;quot; he said, adding that the need for this vaccine was immense since the birth cohort in the affected 171 districts was about 40 lakh annually, requiring about 1 crore doses for a comprehensive coverage.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The current manufacturing capacity of JENVAC is 20 million doses, expandable to 60 million doses based on market requirements. The vaccine is available in both single dose and 5 dose presentations, Krishna M. Ella, Chairman and Managing Director of Bharat Biotech said. &amp;quot;It is yet another milestone for Bharat Biotech.&amp;quot; &lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/india-launches-vaccine-to-prevent-japanese-encephalitis-aarti-dhar-22908.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | India launches vaccine to prevent Japanese encephalitis-Aarti Dhar | Im4change.org</title>
    <meta name="description" content="
-The Hindu



JENVAC is the first vaccine to be manufactured in the public-private partnership mode


India on Friday launched its first indigenous vaccine to protect children from Japanese encephalitis. Until now, the country has been importing the vaccine from China.


The Vero cell-derived..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>India launches vaccine to prevent Japanese encephalitis-Aarti Dhar</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Hindu</div><p align="justify"><br /><em>JENVAC is the first vaccine to be manufactured in the public-private partnership mode</em></p><p align="justify">India on Friday launched its first indigenous vaccine to protect children from Japanese encephalitis. Until now, the country has been importing the vaccine from China.</p><p align="justify">The Vero cell-derived purified inactivated JE vaccine-JENVAC, which received manufacturing and marketing approvals from the Drug Controller General of India, is the first vaccine to be manufactured in the public-private partnership mode between the Indian Council of Medical Research and Bharat Biotech.</p><p align="justify">The vaccine will provide increased immunogenicity and long-term protection as a result of unique manufacturing technologies.</p><p align="justify">Japanese encephalitis, a mosquito-borne viral infection, is the most common cause of viral encephalitis in eastern Uttar Pradesh (U.P.), affecting 171 districts and claiming hundreds of lives every year. Mortality is higher among children and thousands of them in this area have been rendered disabled by it.</p><p align="justify">The virus strain for this vaccine was isolated in Kolar, Karnataka, during the early 1980s and characterised by the National Institute of Virology at Pune. The strains were transferred to Bharat Biotech for further vaccine development.</p><p align="justify">The most significant benefit JENVAC brings over live attenuated vaccines (those that reduce the harmful effects of pathogens but keep them viable) is that it can be administered during an epidemic as it is a highly purified and inactivated vaccine.</p><p align="justify">In the clinical trials, JENVAC showed superior safety and immunogenicity, in comparison to live vaccine. It met all its primary and secondary endpoints in the age group of 1-50 years, after 1 or 2 doses in vaccination. Phase III trials showed 98.7 per cent sero-protection 28 days after the first dose, and 99.8 per cent sero-protection 28 days after the second dose.</p><p align="justify">The results proved that JENVAC can be administered as a single dose during epidemics for mass vaccination campaigns and also as a two-dose schedule during routine immunisation as part of the National immunisation programme in endemic regions.</p><p align="justify">Bharat Biotech will pursue a dual pricing strategy for JENVAC to cater to the needs of government and private agencies. While the price is expected to be around Rs 160 per dose in the open market, the price for government agencies is still being negotiated.</p><p align="justify">Describing the vaccine as an &quot;Indian solution for an Indian problem&quot;, Union Health and Family Welfare Minister Ghulam Nabi Azad said this completely indigenous vaccine was an outstanding example of public-private partnership and a remarkable milestone in the emergence of India as an innovative and self-sufficient technology hub.</p><p align="justify">&quot;Since we were using a vaccine imported from China, availability was certainly an issue for comprehensive and quick augmentation of the national programme,&quot; he said, adding that the need for this vaccine was immense since the birth cohort in the affected 171 districts was about 40 lakh annually, requiring about 1 crore doses for a comprehensive coverage.</p><p align="justify">The current manufacturing capacity of JENVAC is 20 million doses, expandable to 60 million doses based on market requirements. The vaccine is available in both single dose and 5 dose presentations, Krishna M. Ella, Chairman and Managing Director of Bharat Biotech said. &quot;It is yet another milestone for Bharat Biotech.&quot; </p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6801e39740b9b-trace').style.display = (document.getElementById('cakeErr6801e39740b9b-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr6801e39740b9b-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6801e39740b9b-code').style.display = (document.getElementById('cakeErr6801e39740b9b-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr6801e39740b9b-context').style.display = (document.getElementById('cakeErr6801e39740b9b-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr6801e39740b9b-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr6801e39740b9b-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 22754,
		&#039;title&#039; =&gt; &#039;India launches vaccine to prevent Japanese encephalitis-Aarti Dhar&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;JENVAC is the first vaccine to be manufactured in the public-private partnership mode&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
India on Friday launched its first indigenous vaccine to protect children from Japanese encephalitis. Until now, the country has been importing the vaccine from China.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Vero cell-derived purified inactivated JE vaccine-JENVAC, which received manufacturing and marketing approvals from the Drug Controller General of India, is the first vaccine to be manufactured in the public-private partnership mode between the Indian Council of Medical Research and Bharat Biotech.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The vaccine will provide increased immunogenicity and long-term protection as a result of unique manufacturing technologies.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Japanese encephalitis, a mosquito-borne viral infection, is the most common cause of viral encephalitis in eastern Uttar Pradesh (U.P.), affecting 171 districts and claiming hundreds of lives every year. Mortality is higher among children and thousands of them in this area have been rendered disabled by it.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The virus strain for this vaccine was isolated in Kolar, Karnataka, during the early 1980s and characterised by the National Institute of Virology at Pune. The strains were transferred to Bharat Biotech for further vaccine development.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The most significant benefit JENVAC brings over live attenuated vaccines (those that reduce the harmful effects of pathogens but keep them viable) is that it can be administered during an epidemic as it is a highly purified and inactivated vaccine.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In the clinical trials, JENVAC showed superior safety and immunogenicity, in comparison to live vaccine. It met all its primary and secondary endpoints in the age group of 1-50 years, after 1 or 2 doses in vaccination. Phase III trials showed 98.7 per cent sero-protection 28 days after the first dose, and 99.8 per cent sero-protection 28 days after the second dose.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The results proved that JENVAC can be administered as a single dose during epidemics for mass vaccination campaigns and also as a two-dose schedule during routine immunisation as part of the National immunisation programme in endemic regions.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Bharat Biotech will pursue a dual pricing strategy for JENVAC to cater to the needs of government and private agencies. While the price is expected to be around Rs 160 per dose in the open market, the price for government agencies is still being negotiated.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Describing the vaccine as an &amp;quot;Indian solution for an Indian problem&amp;quot;, Union Health and Family Welfare Minister Ghulam Nabi Azad said this completely indigenous vaccine was an outstanding example of public-private partnership and a remarkable milestone in the emergence of India as an innovative and self-sufficient technology hub.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Since we were using a vaccine imported from China, availability was certainly an issue for comprehensive and quick augmentation of the national programme,&amp;quot; he said, adding that the need for this vaccine was immense since the birth cohort in the affected 171 districts was about 40 lakh annually, requiring about 1 crore doses for a comprehensive coverage.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The current manufacturing capacity of JENVAC is 20 million doses, expandable to 60 million doses based on market requirements. The vaccine is available in both single dose and 5 dose presentations, Krishna M. Ella, Chairman and Managing Director of Bharat Biotech said. &amp;quot;It is yet another milestone for Bharat Biotech.&amp;quot; 
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu, 4 October, 2013, http://www.thehindu.com/news/national/india-launches-vaccine-to-prevent-japanese-encephalitis/article5201813.ece?homepage=true&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;india-launches-vaccine-to-prevent-japanese-encephalitis-aarti-dhar-22908&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 22908,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 22754,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | India launches vaccine to prevent Japanese encephalitis-Aarti Dhar&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Vaccination,Encephalitis,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Hindu



JENVAC is the first vaccine to be manufactured in the public-private partnership mode


India on Friday launched its first indigenous vaccine to protect children from Japanese encephalitis. Until now, the country has been importing the vaccine from China.


The Vero cell-derived...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;JENVAC is the first vaccine to be manufactured in the public-private partnership mode&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;India on Friday launched its first indigenous vaccine to protect children from Japanese encephalitis. Until now, the country has been importing the vaccine from China.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Vero cell-derived purified inactivated JE vaccine-JENVAC, which received manufacturing and marketing approvals from the Drug Controller General of India, is the first vaccine to be manufactured in the public-private partnership mode between the Indian Council of Medical Research and Bharat Biotech.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The vaccine will provide increased immunogenicity and long-term protection as a result of unique manufacturing technologies.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Japanese encephalitis, a mosquito-borne viral infection, is the most common cause of viral encephalitis in eastern Uttar Pradesh (U.P.), affecting 171 districts and claiming hundreds of lives every year. Mortality is higher among children and thousands of them in this area have been rendered disabled by it.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The virus strain for this vaccine was isolated in Kolar, Karnataka, during the early 1980s and characterised by the National Institute of Virology at Pune. The strains were transferred to Bharat Biotech for further vaccine development.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The most significant benefit JENVAC brings over live attenuated vaccines (those that reduce the harmful effects of pathogens but keep them viable) is that it can be administered during an epidemic as it is a highly purified and inactivated vaccine.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In the clinical trials, JENVAC showed superior safety and immunogenicity, in comparison to live vaccine. It met all its primary and secondary endpoints in the age group of 1-50 years, after 1 or 2 doses in vaccination. Phase III trials showed 98.7 per cent sero-protection 28 days after the first dose, and 99.8 per cent sero-protection 28 days after the second dose.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The results proved that JENVAC can be administered as a single dose during epidemics for mass vaccination campaigns and also as a two-dose schedule during routine immunisation as part of the National immunisation programme in endemic regions.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Bharat Biotech will pursue a dual pricing strategy for JENVAC to cater to the needs of government and private agencies. While the price is expected to be around Rs 160 per dose in the open market, the price for government agencies is still being negotiated.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Describing the vaccine as an &amp;quot;Indian solution for an Indian problem&amp;quot;, Union Health and Family Welfare Minister Ghulam Nabi Azad said this completely indigenous vaccine was an outstanding example of public-private partnership and a remarkable milestone in the emergence of India as an innovative and self-sufficient technology hub.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Since we were using a vaccine imported from China, availability was certainly an issue for comprehensive and quick augmentation of the national programme,&amp;quot; he said, adding that the need for this vaccine was immense since the birth cohort in the affected 171 districts was about 40 lakh annually, requiring about 1 crore doses for a comprehensive coverage.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The current manufacturing capacity of JENVAC is 20 million doses, expandable to 60 million doses based on market requirements. The vaccine is available in both single dose and 5 dose presentations, Krishna M. Ella, Chairman and Managing Director of Bharat Biotech said. &amp;quot;It is yet another milestone for Bharat Biotech.&amp;quot; &lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 22754,
	&#039;title&#039; =&gt; &#039;India launches vaccine to prevent Japanese encephalitis-Aarti Dhar&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;JENVAC is the first vaccine to be manufactured in the public-private partnership mode&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
India on Friday launched its first indigenous vaccine to protect children from Japanese encephalitis. Until now, the country has been importing the vaccine from China.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Vero cell-derived purified inactivated JE vaccine-JENVAC, which received manufacturing and marketing approvals from the Drug Controller General of India, is the first vaccine to be manufactured in the public-private partnership mode between the Indian Council of Medical Research and Bharat Biotech.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The vaccine will provide increased immunogenicity and long-term protection as a result of unique manufacturing technologies.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Japanese encephalitis, a mosquito-borne viral infection, is the most common cause of viral encephalitis in eastern Uttar Pradesh (U.P.), affecting 171 districts and claiming hundreds of lives every year. Mortality is higher among children and thousands of them in this area have been rendered disabled by it.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The virus strain for this vaccine was isolated in Kolar, Karnataka, during the early 1980s and characterised by the National Institute of Virology at Pune. The strains were transferred to Bharat Biotech for further vaccine development.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The most significant benefit JENVAC brings over live attenuated vaccines (those that reduce the harmful effects of pathogens but keep them viable) is that it can be administered during an epidemic as it is a highly purified and inactivated vaccine.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In the clinical trials, JENVAC showed superior safety and immunogenicity, in comparison to live vaccine. It met all its primary and secondary endpoints in the age group of 1-50 years, after 1 or 2 doses in vaccination. Phase III trials showed 98.7 per cent sero-protection 28 days after the first dose, and 99.8 per cent sero-protection 28 days after the second dose.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The results proved that JENVAC can be administered as a single dose during epidemics for mass vaccination campaigns and also as a two-dose schedule during routine immunisation as part of the National immunisation programme in endemic regions.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Bharat Biotech will pursue a dual pricing strategy for JENVAC to cater to the needs of government and private agencies. While the price is expected to be around Rs 160 per dose in the open market, the price for government agencies is still being negotiated.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Describing the vaccine as an &amp;quot;Indian solution for an Indian problem&amp;quot;, Union Health and Family Welfare Minister Ghulam Nabi Azad said this completely indigenous vaccine was an outstanding example of public-private partnership and a remarkable milestone in the emergence of India as an innovative and self-sufficient technology hub.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Since we were using a vaccine imported from China, availability was certainly an issue for comprehensive and quick augmentation of the national programme,&amp;quot; he said, adding that the need for this vaccine was immense since the birth cohort in the affected 171 districts was about 40 lakh annually, requiring about 1 crore doses for a comprehensive coverage.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The current manufacturing capacity of JENVAC is 20 million doses, expandable to 60 million doses based on market requirements. The vaccine is available in both single dose and 5 dose presentations, Krishna M. Ella, Chairman and Managing Director of Bharat Biotech said. &amp;quot;It is yet another milestone for Bharat Biotech.&amp;quot; 
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu, 4 October, 2013, http://www.thehindu.com/news/national/india-launches-vaccine-to-prevent-japanese-encephalitis/article5201813.ece?homepage=true&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;india-launches-vaccine-to-prevent-japanese-encephalitis-aarti-dhar-22908&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 22908,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 22754
$metaTitle = &#039;LATEST NEWS UPDATES | India launches vaccine to prevent Japanese encephalitis-Aarti Dhar&#039;
$metaKeywords = &#039;Vaccination,Encephalitis,Health&#039;
$metaDesc = &#039;
-The Hindu



JENVAC is the first vaccine to be manufactured in the public-private partnership mode


India on Friday launched its first indigenous vaccine to protect children from Japanese encephalitis. Until now, the country has been importing the vaccine from China.


The Vero cell-derived...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;JENVAC is the first vaccine to be manufactured in the public-private partnership mode&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;India on Friday launched its first indigenous vaccine to protect children from Japanese encephalitis. Until now, the country has been importing the vaccine from China.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Vero cell-derived purified inactivated JE vaccine-JENVAC, which received manufacturing and marketing approvals from the Drug Controller General of India, is the first vaccine to be manufactured in the public-private partnership mode between the Indian Council of Medical Research and Bharat Biotech.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The vaccine will provide increased immunogenicity and long-term protection as a result of unique manufacturing technologies.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Japanese encephalitis, a mosquito-borne viral infection, is the most common cause of viral encephalitis in eastern Uttar Pradesh (U.P.), affecting 171 districts and claiming hundreds of lives every year. Mortality is higher among children and thousands of them in this area have been rendered disabled by it.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The virus strain for this vaccine was isolated in Kolar, Karnataka, during the early 1980s and characterised by the National Institute of Virology at Pune. The strains were transferred to Bharat Biotech for further vaccine development.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The most significant benefit JENVAC brings over live attenuated vaccines (those that reduce the harmful effects of pathogens but keep them viable) is that it can be administered during an epidemic as it is a highly purified and inactivated vaccine.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In the clinical trials, JENVAC showed superior safety and immunogenicity, in comparison to live vaccine. It met all its primary and secondary endpoints in the age group of 1-50 years, after 1 or 2 doses in vaccination. Phase III trials showed 98.7 per cent sero-protection 28 days after the first dose, and 99.8 per cent sero-protection 28 days after the second dose.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The results proved that JENVAC can be administered as a single dose during epidemics for mass vaccination campaigns and also as a two-dose schedule during routine immunisation as part of the National immunisation programme in endemic regions.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Bharat Biotech will pursue a dual pricing strategy for JENVAC to cater to the needs of government and private agencies. While the price is expected to be around Rs 160 per dose in the open market, the price for government agencies is still being negotiated.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Describing the vaccine as an &amp;quot;Indian solution for an Indian problem&amp;quot;, Union Health and Family Welfare Minister Ghulam Nabi Azad said this completely indigenous vaccine was an outstanding example of public-private partnership and a remarkable milestone in the emergence of India as an innovative and self-sufficient technology hub.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Since we were using a vaccine imported from China, availability was certainly an issue for comprehensive and quick augmentation of the national programme,&amp;quot; he said, adding that the need for this vaccine was immense since the birth cohort in the affected 171 districts was about 40 lakh annually, requiring about 1 crore doses for a comprehensive coverage.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The current manufacturing capacity of JENVAC is 20 million doses, expandable to 60 million doses based on market requirements. The vaccine is available in both single dose and 5 dose presentations, Krishna M. Ella, Chairman and Managing Director of Bharat Biotech said. &amp;quot;It is yet another milestone for Bharat Biotech.&amp;quot; &lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/india-launches-vaccine-to-prevent-japanese-encephalitis-aarti-dhar-22908.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | India launches vaccine to prevent Japanese encephalitis-Aarti Dhar | Im4change.org</title>
    <meta name="description" content="
-The Hindu



JENVAC is the first vaccine to be manufactured in the public-private partnership mode


India on Friday launched its first indigenous vaccine to protect children from Japanese encephalitis. Until now, the country has been importing the vaccine from China.


The Vero cell-derived..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>India launches vaccine to prevent Japanese encephalitis-Aarti Dhar</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Hindu</div><p align="justify"><br /><em>JENVAC is the first vaccine to be manufactured in the public-private partnership mode</em></p><p align="justify">India on Friday launched its first indigenous vaccine to protect children from Japanese encephalitis. Until now, the country has been importing the vaccine from China.</p><p align="justify">The Vero cell-derived purified inactivated JE vaccine-JENVAC, which received manufacturing and marketing approvals from the Drug Controller General of India, is the first vaccine to be manufactured in the public-private partnership mode between the Indian Council of Medical Research and Bharat Biotech.</p><p align="justify">The vaccine will provide increased immunogenicity and long-term protection as a result of unique manufacturing technologies.</p><p align="justify">Japanese encephalitis, a mosquito-borne viral infection, is the most common cause of viral encephalitis in eastern Uttar Pradesh (U.P.), affecting 171 districts and claiming hundreds of lives every year. Mortality is higher among children and thousands of them in this area have been rendered disabled by it.</p><p align="justify">The virus strain for this vaccine was isolated in Kolar, Karnataka, during the early 1980s and characterised by the National Institute of Virology at Pune. The strains were transferred to Bharat Biotech for further vaccine development.</p><p align="justify">The most significant benefit JENVAC brings over live attenuated vaccines (those that reduce the harmful effects of pathogens but keep them viable) is that it can be administered during an epidemic as it is a highly purified and inactivated vaccine.</p><p align="justify">In the clinical trials, JENVAC showed superior safety and immunogenicity, in comparison to live vaccine. It met all its primary and secondary endpoints in the age group of 1-50 years, after 1 or 2 doses in vaccination. Phase III trials showed 98.7 per cent sero-protection 28 days after the first dose, and 99.8 per cent sero-protection 28 days after the second dose.</p><p align="justify">The results proved that JENVAC can be administered as a single dose during epidemics for mass vaccination campaigns and also as a two-dose schedule during routine immunisation as part of the National immunisation programme in endemic regions.</p><p align="justify">Bharat Biotech will pursue a dual pricing strategy for JENVAC to cater to the needs of government and private agencies. While the price is expected to be around Rs 160 per dose in the open market, the price for government agencies is still being negotiated.</p><p align="justify">Describing the vaccine as an &quot;Indian solution for an Indian problem&quot;, Union Health and Family Welfare Minister Ghulam Nabi Azad said this completely indigenous vaccine was an outstanding example of public-private partnership and a remarkable milestone in the emergence of India as an innovative and self-sufficient technology hub.</p><p align="justify">&quot;Since we were using a vaccine imported from China, availability was certainly an issue for comprehensive and quick augmentation of the national programme,&quot; he said, adding that the need for this vaccine was immense since the birth cohort in the affected 171 districts was about 40 lakh annually, requiring about 1 crore doses for a comprehensive coverage.</p><p align="justify">The current manufacturing capacity of JENVAC is 20 million doses, expandable to 60 million doses based on market requirements. The vaccine is available in both single dose and 5 dose presentations, Krishna M. Ella, Chairman and Managing Director of Bharat Biotech said. &quot;It is yet another milestone for Bharat Biotech.&quot; </p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 22754,
		'title' => 'India launches vaccine to prevent Japanese encephalitis-Aarti Dhar',
		'subheading' => '',
		'description' => '<div align="justify">
-The Hindu
</div>
<p align="justify">
<br />
<em>JENVAC is the first vaccine to be manufactured in the public-private partnership mode</em>
</p>
<p align="justify">
India on Friday launched its first indigenous vaccine to protect children from Japanese encephalitis. Until now, the country has been importing the vaccine from China.
</p>
<p align="justify">
The Vero cell-derived purified inactivated JE vaccine-JENVAC, which received manufacturing and marketing approvals from the Drug Controller General of India, is the first vaccine to be manufactured in the public-private partnership mode between the Indian Council of Medical Research and Bharat Biotech.
</p>
<p align="justify">
The vaccine will provide increased immunogenicity and long-term protection as a result of unique manufacturing technologies.
</p>
<p align="justify">
Japanese encephalitis, a mosquito-borne viral infection, is the most common cause of viral encephalitis in eastern Uttar Pradesh (U.P.), affecting 171 districts and claiming hundreds of lives every year. Mortality is higher among children and thousands of them in this area have been rendered disabled by it.
</p>
<p align="justify">
The virus strain for this vaccine was isolated in Kolar, Karnataka, during the early 1980s and characterised by the National Institute of Virology at Pune. The strains were transferred to Bharat Biotech for further vaccine development.
</p>
<p align="justify">
The most significant benefit JENVAC brings over live attenuated vaccines (those that reduce the harmful effects of pathogens but keep them viable) is that it can be administered during an epidemic as it is a highly purified and inactivated vaccine.
</p>
<p align="justify">
In the clinical trials, JENVAC showed superior safety and immunogenicity, in comparison to live vaccine. It met all its primary and secondary endpoints in the age group of 1-50 years, after 1 or 2 doses in vaccination. Phase III trials showed 98.7 per cent sero-protection 28 days after the first dose, and 99.8 per cent sero-protection 28 days after the second dose.
</p>
<p align="justify">
The results proved that JENVAC can be administered as a single dose during epidemics for mass vaccination campaigns and also as a two-dose schedule during routine immunisation as part of the National immunisation programme in endemic regions.
</p>
<p align="justify">
Bharat Biotech will pursue a dual pricing strategy for JENVAC to cater to the needs of government and private agencies. While the price is expected to be around Rs 160 per dose in the open market, the price for government agencies is still being negotiated.
</p>
<p align="justify">
Describing the vaccine as an &quot;Indian solution for an Indian problem&quot;, Union Health and Family Welfare Minister Ghulam Nabi Azad said this completely indigenous vaccine was an outstanding example of public-private partnership and a remarkable milestone in the emergence of India as an innovative and self-sufficient technology hub.
</p>
<p align="justify">
&quot;Since we were using a vaccine imported from China, availability was certainly an issue for comprehensive and quick augmentation of the national programme,&quot; he said, adding that the need for this vaccine was immense since the birth cohort in the affected 171 districts was about 40 lakh annually, requiring about 1 crore doses for a comprehensive coverage.
</p>
<p align="justify">
The current manufacturing capacity of JENVAC is 20 million doses, expandable to 60 million doses based on market requirements. The vaccine is available in both single dose and 5 dose presentations, Krishna M. Ella, Chairman and Managing Director of Bharat Biotech said. &quot;It is yet another milestone for Bharat Biotech.&quot; 
</p>',
		'credit_writer' => 'The Hindu, 4 October, 2013, http://www.thehindu.com/news/national/india-launches-vaccine-to-prevent-japanese-encephalitis/article5201813.ece?homepage=true',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'india-launches-vaccine-to-prevent-japanese-encephalitis-aarti-dhar-22908',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 22908,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 22754,
	'metaTitle' => 'LATEST NEWS UPDATES | India launches vaccine to prevent Japanese encephalitis-Aarti Dhar',
	'metaKeywords' => 'Vaccination,Encephalitis,Health',
	'metaDesc' => '
-The Hindu



JENVAC is the first vaccine to be manufactured in the public-private partnership mode


India on Friday launched its first indigenous vaccine to protect children from Japanese encephalitis. Until now, the country has been importing the vaccine from China.


The Vero cell-derived...',
	'disp' => '<div align="justify">-The Hindu</div><p align="justify"><br /><em>JENVAC is the first vaccine to be manufactured in the public-private partnership mode</em></p><p align="justify">India on Friday launched its first indigenous vaccine to protect children from Japanese encephalitis. Until now, the country has been importing the vaccine from China.</p><p align="justify">The Vero cell-derived purified inactivated JE vaccine-JENVAC, which received manufacturing and marketing approvals from the Drug Controller General of India, is the first vaccine to be manufactured in the public-private partnership mode between the Indian Council of Medical Research and Bharat Biotech.</p><p align="justify">The vaccine will provide increased immunogenicity and long-term protection as a result of unique manufacturing technologies.</p><p align="justify">Japanese encephalitis, a mosquito-borne viral infection, is the most common cause of viral encephalitis in eastern Uttar Pradesh (U.P.), affecting 171 districts and claiming hundreds of lives every year. Mortality is higher among children and thousands of them in this area have been rendered disabled by it.</p><p align="justify">The virus strain for this vaccine was isolated in Kolar, Karnataka, during the early 1980s and characterised by the National Institute of Virology at Pune. The strains were transferred to Bharat Biotech for further vaccine development.</p><p align="justify">The most significant benefit JENVAC brings over live attenuated vaccines (those that reduce the harmful effects of pathogens but keep them viable) is that it can be administered during an epidemic as it is a highly purified and inactivated vaccine.</p><p align="justify">In the clinical trials, JENVAC showed superior safety and immunogenicity, in comparison to live vaccine. It met all its primary and secondary endpoints in the age group of 1-50 years, after 1 or 2 doses in vaccination. Phase III trials showed 98.7 per cent sero-protection 28 days after the first dose, and 99.8 per cent sero-protection 28 days after the second dose.</p><p align="justify">The results proved that JENVAC can be administered as a single dose during epidemics for mass vaccination campaigns and also as a two-dose schedule during routine immunisation as part of the National immunisation programme in endemic regions.</p><p align="justify">Bharat Biotech will pursue a dual pricing strategy for JENVAC to cater to the needs of government and private agencies. While the price is expected to be around Rs 160 per dose in the open market, the price for government agencies is still being negotiated.</p><p align="justify">Describing the vaccine as an &quot;Indian solution for an Indian problem&quot;, Union Health and Family Welfare Minister Ghulam Nabi Azad said this completely indigenous vaccine was an outstanding example of public-private partnership and a remarkable milestone in the emergence of India as an innovative and self-sufficient technology hub.</p><p align="justify">&quot;Since we were using a vaccine imported from China, availability was certainly an issue for comprehensive and quick augmentation of the national programme,&quot; he said, adding that the need for this vaccine was immense since the birth cohort in the affected 171 districts was about 40 lakh annually, requiring about 1 crore doses for a comprehensive coverage.</p><p align="justify">The current manufacturing capacity of JENVAC is 20 million doses, expandable to 60 million doses based on market requirements. The vaccine is available in both single dose and 5 dose presentations, Krishna M. Ella, Chairman and Managing Director of Bharat Biotech said. &quot;It is yet another milestone for Bharat Biotech.&quot; </p>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 22754,
	'title' => 'India launches vaccine to prevent Japanese encephalitis-Aarti Dhar',
	'subheading' => '',
	'description' => '<div align="justify">
-The Hindu
</div>
<p align="justify">
<br />
<em>JENVAC is the first vaccine to be manufactured in the public-private partnership mode</em>
</p>
<p align="justify">
India on Friday launched its first indigenous vaccine to protect children from Japanese encephalitis. Until now, the country has been importing the vaccine from China.
</p>
<p align="justify">
The Vero cell-derived purified inactivated JE vaccine-JENVAC, which received manufacturing and marketing approvals from the Drug Controller General of India, is the first vaccine to be manufactured in the public-private partnership mode between the Indian Council of Medical Research and Bharat Biotech.
</p>
<p align="justify">
The vaccine will provide increased immunogenicity and long-term protection as a result of unique manufacturing technologies.
</p>
<p align="justify">
Japanese encephalitis, a mosquito-borne viral infection, is the most common cause of viral encephalitis in eastern Uttar Pradesh (U.P.), affecting 171 districts and claiming hundreds of lives every year. Mortality is higher among children and thousands of them in this area have been rendered disabled by it.
</p>
<p align="justify">
The virus strain for this vaccine was isolated in Kolar, Karnataka, during the early 1980s and characterised by the National Institute of Virology at Pune. The strains were transferred to Bharat Biotech for further vaccine development.
</p>
<p align="justify">
The most significant benefit JENVAC brings over live attenuated vaccines (those that reduce the harmful effects of pathogens but keep them viable) is that it can be administered during an epidemic as it is a highly purified and inactivated vaccine.
</p>
<p align="justify">
In the clinical trials, JENVAC showed superior safety and immunogenicity, in comparison to live vaccine. It met all its primary and secondary endpoints in the age group of 1-50 years, after 1 or 2 doses in vaccination. Phase III trials showed 98.7 per cent sero-protection 28 days after the first dose, and 99.8 per cent sero-protection 28 days after the second dose.
</p>
<p align="justify">
The results proved that JENVAC can be administered as a single dose during epidemics for mass vaccination campaigns and also as a two-dose schedule during routine immunisation as part of the National immunisation programme in endemic regions.
</p>
<p align="justify">
Bharat Biotech will pursue a dual pricing strategy for JENVAC to cater to the needs of government and private agencies. While the price is expected to be around Rs 160 per dose in the open market, the price for government agencies is still being negotiated.
</p>
<p align="justify">
Describing the vaccine as an &quot;Indian solution for an Indian problem&quot;, Union Health and Family Welfare Minister Ghulam Nabi Azad said this completely indigenous vaccine was an outstanding example of public-private partnership and a remarkable milestone in the emergence of India as an innovative and self-sufficient technology hub.
</p>
<p align="justify">
&quot;Since we were using a vaccine imported from China, availability was certainly an issue for comprehensive and quick augmentation of the national programme,&quot; he said, adding that the need for this vaccine was immense since the birth cohort in the affected 171 districts was about 40 lakh annually, requiring about 1 crore doses for a comprehensive coverage.
</p>
<p align="justify">
The current manufacturing capacity of JENVAC is 20 million doses, expandable to 60 million doses based on market requirements. The vaccine is available in both single dose and 5 dose presentations, Krishna M. Ella, Chairman and Managing Director of Bharat Biotech said. &quot;It is yet another milestone for Bharat Biotech.&quot; 
</p>',
	'credit_writer' => 'The Hindu, 4 October, 2013, http://www.thehindu.com/news/national/india-launches-vaccine-to-prevent-japanese-encephalitis/article5201813.ece?homepage=true',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'india-launches-vaccine-to-prevent-japanese-encephalitis-aarti-dhar-22908',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 22908,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {},
		(int) 2 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 22754
$metaTitle = 'LATEST NEWS UPDATES | India launches vaccine to prevent Japanese encephalitis-Aarti Dhar'
$metaKeywords = 'Vaccination,Encephalitis,Health'
$metaDesc = '
-The Hindu



JENVAC is the first vaccine to be manufactured in the public-private partnership mode


India on Friday launched its first indigenous vaccine to protect children from Japanese encephalitis. Until now, the country has been importing the vaccine from China.


The Vero cell-derived...'
$disp = '<div align="justify">-The Hindu</div><p align="justify"><br /><em>JENVAC is the first vaccine to be manufactured in the public-private partnership mode</em></p><p align="justify">India on Friday launched its first indigenous vaccine to protect children from Japanese encephalitis. Until now, the country has been importing the vaccine from China.</p><p align="justify">The Vero cell-derived purified inactivated JE vaccine-JENVAC, which received manufacturing and marketing approvals from the Drug Controller General of India, is the first vaccine to be manufactured in the public-private partnership mode between the Indian Council of Medical Research and Bharat Biotech.</p><p align="justify">The vaccine will provide increased immunogenicity and long-term protection as a result of unique manufacturing technologies.</p><p align="justify">Japanese encephalitis, a mosquito-borne viral infection, is the most common cause of viral encephalitis in eastern Uttar Pradesh (U.P.), affecting 171 districts and claiming hundreds of lives every year. Mortality is higher among children and thousands of them in this area have been rendered disabled by it.</p><p align="justify">The virus strain for this vaccine was isolated in Kolar, Karnataka, during the early 1980s and characterised by the National Institute of Virology at Pune. The strains were transferred to Bharat Biotech for further vaccine development.</p><p align="justify">The most significant benefit JENVAC brings over live attenuated vaccines (those that reduce the harmful effects of pathogens but keep them viable) is that it can be administered during an epidemic as it is a highly purified and inactivated vaccine.</p><p align="justify">In the clinical trials, JENVAC showed superior safety and immunogenicity, in comparison to live vaccine. It met all its primary and secondary endpoints in the age group of 1-50 years, after 1 or 2 doses in vaccination. Phase III trials showed 98.7 per cent sero-protection 28 days after the first dose, and 99.8 per cent sero-protection 28 days after the second dose.</p><p align="justify">The results proved that JENVAC can be administered as a single dose during epidemics for mass vaccination campaigns and also as a two-dose schedule during routine immunisation as part of the National immunisation programme in endemic regions.</p><p align="justify">Bharat Biotech will pursue a dual pricing strategy for JENVAC to cater to the needs of government and private agencies. While the price is expected to be around Rs 160 per dose in the open market, the price for government agencies is still being negotiated.</p><p align="justify">Describing the vaccine as an &quot;Indian solution for an Indian problem&quot;, Union Health and Family Welfare Minister Ghulam Nabi Azad said this completely indigenous vaccine was an outstanding example of public-private partnership and a remarkable milestone in the emergence of India as an innovative and self-sufficient technology hub.</p><p align="justify">&quot;Since we were using a vaccine imported from China, availability was certainly an issue for comprehensive and quick augmentation of the national programme,&quot; he said, adding that the need for this vaccine was immense since the birth cohort in the affected 171 districts was about 40 lakh annually, requiring about 1 crore doses for a comprehensive coverage.</p><p align="justify">The current manufacturing capacity of JENVAC is 20 million doses, expandable to 60 million doses based on market requirements. The vaccine is available in both single dose and 5 dose presentations, Krishna M. Ella, Chairman and Managing Director of Bharat Biotech said. &quot;It is yet another milestone for Bharat Biotech.&quot; </p>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

India launches vaccine to prevent Japanese encephalitis-Aarti Dhar

-The Hindu JENVAC is the first vaccine to be manufactured in the public-private partnership mode India on Friday launched its first indigenous vaccine to protect children from Japanese encephalitis. Until now, the country has been importing the vaccine from China. The Vero cell-derived purified inactivated JE vaccine-JENVAC, which received manufacturing and marketing approvals from the Drug Controller General of India, is the first vaccine to be manufactured in the public-private partnership mode between the Indian Council of Medical Research and Bharat Biotech. The vaccine will provide increased immunogenicity and long-term protection as a result of unique manufacturing technologies. Japanese encephalitis, a mosquito-borne viral infection, is the most common cause of viral encephalitis in eastern Uttar Pradesh (U.P.), affecting 171 districts and claiming hundreds of lives every year. Mortality is higher among children and thousands of them in this area have been rendered disabled by it. The virus strain for this vaccine was isolated in Kolar, Karnataka, during the early 1980s and characterised by the National Institute of Virology at Pune. The strains were transferred to Bharat Biotech for further vaccine development. The most significant benefit JENVAC brings over live attenuated vaccines (those that reduce the harmful effects of pathogens but keep them viable) is that it can be administered during an epidemic as it is a highly purified and inactivated vaccine. In the clinical trials, JENVAC showed superior safety and immunogenicity, in comparison to live vaccine. It met all its primary and secondary endpoints in the age group of 1-50 years, after 1 or 2 doses in vaccination. Phase III trials showed 98.7 per cent sero-protection 28 days after the first dose, and 99.8 per cent sero-protection 28 days after the second dose. The results proved that JENVAC can be administered as a single dose during epidemics for mass vaccination campaigns and also as a two-dose schedule during routine immunisation as part of the National immunisation programme in endemic regions. Bharat Biotech will pursue a dual pricing strategy for JENVAC to cater to the needs of government and private agencies. While the price is expected to be around Rs 160 per dose in the open market, the price for government agencies is still being negotiated. Describing the vaccine as an "Indian solution for an Indian problem", Union Health and Family Welfare Minister Ghulam Nabi Azad said this completely indigenous vaccine was an outstanding example of public-private partnership and a remarkable milestone in the emergence of India as an innovative and self-sufficient technology hub. "Since we were using a vaccine imported from China, availability was certainly an issue for comprehensive and quick augmentation of the national programme," he said, adding that the need for this vaccine was immense since the birth cohort in the affected 171 districts was about 40 lakh annually, requiring about 1 crore doses for a comprehensive coverage. The current manufacturing capacity of JENVAC is 20 million doses, expandable to 60 million doses based on market requirements. The vaccine is available in both single dose and 5 dose presentations, Krishna M. Ella, Chairman and Managing Director of Bharat Biotech said. "It is yet another milestone for Bharat Biotech."